吸入可能医薬品の世界市場レポート 2025年

吸入可能医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.6％で500億米ドルに成長します。予測期間の成長は、ヘルスケア支出の増加、生物製剤の需要拡大、個別化医療への注目の高まり、希少疾病用医薬品への規制支援などに起因すると考えられます。予測期間における主な動向としては、動物医療における呼吸器系薬剤の進歩、技術革新、償還政策の改善などが挙げられます。

呼吸器系疾患の有病率の上昇は、今後数年間、吸入薬市場の成長を促進すると予想されます。呼吸器疾患は、肺、気管支、気管、喉頭、咽頭、鼻腔を含む呼吸器系に影響を及ぼします。吸入可能医薬品は、肺に直接薬剤を投与するため、さまざまな呼吸器疾患にとって重要かつ効果的な治療オプションです。例えば、2023年12月にオーストラリア統計局が発表したところによると、2022年には人口の2.5％（638,100人）が慢性閉塞性肺疾患（COPD）に罹患しており、男性（2.4％）と女性（2.6％）では同様の割合でした。現在日常的に喫煙している人は、元喫煙者（4.4％）および非喫煙者（1.6％）に比べ、COPD（8.1％）に罹患する可能性が有意に高かったです。したがって、呼吸器疾患の有病率の増加は、将来的に吸入薬市場を促進する可能性が高いです。

個別化医療がますます重視されるようになったことで、吸入可能な医薬品市場の成長が当面促進される見通しです。精密医療としても知られる個別化医療は、患者の遺伝子、環境、ライフスタイルの個人差を考慮した新しい治療アプローチを意味します。吸入性医薬品の文脈では、個別化医療は個々の遺伝子、バイオマーカー、臨床的要因に基づいて治療法を調整することを含みます。このアプローチは、吸入可能な薬物療法の有効性と、呼吸器ケアにおける全体的な患者の満足度を高める可能性があります。例えば、2023年2月の個別化医療連合（Personalized Medicine Coalition）のデータでは、2022年に米国食品医薬品局（FDA）が承認した新医薬品のうち、個別化薬が34％を占めたことが明らかになった。さらに、それ以前の8年間は、いずれも25％以上を占めていました。したがって、個別化医療が重視されるようになっていることは、吸入可能医薬品市場の促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界吸入可能医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の吸入可能医薬品市場：成長率分析
• 世界の吸入可能医薬品市場の実績：規模と成長, 2019-2024
• 世界の吸入可能医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界吸入可能医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の吸入可能医薬品市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エアロゾル
• 乾燥粉末製剤
• スプレー
• 世界の吸入可能医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 薬局
• その他の流通チャネル
• 世界の吸入可能医薬品市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 呼吸器疾患
• 呼吸器系以外の疾患
• 世界の吸入可能医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大人
• 小児科
• 高齢者
• 世界の吸入可能医薬品市場、エアロゾルの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 定量噴霧式吸入器（MDI）
• ネブライザー
• ソフトミスト吸入器
• 世界の吸入可能医薬品市場、乾燥粉末製剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドライパウダー吸入器（DPI）
• ブリスターパック
• カプセル
• 世界の吸入可能医薬品市場、スプレーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鼻スプレー
• 経口スプレー
• 皮下スプレー

第7章 地域別・国別分析

• 世界の吸入可能医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の吸入可能医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 吸入可能医薬品市場：競合情勢
• 吸入可能医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline Plc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Catalent Inc.
• Sumitomo Pharma Co. Ltd.
• Intertek Group plc
• AptarGroup Inc.
• Cipla Inc.
• Glenmark Pharmaceuticals Inc.
• Piramal Pharma Ltd.
• Zambon S.p.A.
• Sunovion Pharmaceuticals Inc.
• Nelson Laboratories LLC
• Vectura Group Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 吸入可能医薬品市場2029：新たな機会を提供する国
• 吸入可能医薬品市場2029：新たな機会を提供するセグメント
• 吸入可能医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Inhalable drugs are medications delivered through the lungs via inhalation, typically using devices such as inhalers or nebulizers. These drugs are primarily used to treat respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and other lung disorders. This method facilitates direct delivery of the medication to the respiratory system, providing quick and effective relief.

The primary forms of inhalable drugs include aerosols, dry powder formulations, and sprays. An aerosol is a suspension of particles or droplets in the air, encompassing airborne dust, fog, odors, or smoke. These products are distributed through various channels, including hospital pharmacies, pharmacy stores, and others. They find applications in treating both respiratory and non-respiratory diseases, catering to diverse end-users such as adults, pediatrics, and geriatrics.

The inhalable drug market research report is one of a series of new reports from The Business Research Company that provides inhalable drug market statistics, including the inhalable drug industry's global market size, regional shares, competitors with an inhalable drug market share, detailed inhalable drug market segments, market trends, and opportunities, and any further data you may need to thrive in the inhalable drug industry. This inhalable drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inhalable drugs market size has grown strongly in recent years. It will grow from $35.06 billion in 2024 to $37.27 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increased geriatric population, patient preference for non-invasive treatments, increased focus on respiratory health, emerging markets growth

The inhalable drugs market size is expected to see strong growth in the next few years. It will grow to $50 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to growing healthcare spending, growing demand for biologics, increasing focus on personalized medicine, regulatory support for orphan drugs. Major trends in the forecast period include advanced respiratory drugs in veterinary medicine, technological innovation, and improved reimbursement policies.

The rising prevalence of respiratory diseases is expected to drive the growth of the inhalable drug market in the coming years. Respiratory diseases affect the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Inhalable drugs are a vital and effective treatment option for various respiratory disorders, as they deliver medication directly to the lungs. For example, in December 2023, the Australian Bureau of Statistics reported that in 2022, 2.5% of the population (638,100 individuals) had chronic obstructive pulmonary disease (COPD), with similar rates among males (2.4%) and females (2.6%). Current daily smokers were significantly more likely to have COPD (8.1%) compared to ex-smokers (4.4%) and non-smokers (1.6%). Therefore, the growing prevalence of respiratory diseases will likely propel the inhalable drug market in the future.

The increasing emphasis on personalized medicine is poised to propel the growth of the inhalable drug market in the foreseeable future. Personalized medicine, also known as precision medicine, represents a novel treatment approach that considers individual variations in patients' genes, environments, and lifestyles. In the context of inhalable pharmaceuticals, personalized medicine involves tailoring therapies based on individual genetic, biomarker, and clinical factors. This approach has the potential to enhance the effectiveness of inhalable medication therapy and overall patient satisfaction in respiratory care. For example, data from the Personalized Medicine Coalition in February 2023 revealed that personalized medications constituted 34% of new pharmaceuticals approved by the US Food and Drug Administration in 2022. Moreover, they had accounted for at least 25% of licenses in each of the previous eight years. Hence, the growing emphasis on personalized medicine serves as a driving factor for the inhalable drug market.

Product innovations have emerged as a significant trend gaining traction in the inhalable drug market, with major companies strategically focusing on advancing inhalable drugs to maintain their market standing. A notable example is DMV-Fonterra Excipients GmbH & Co. KG, a Germany-based pharmaceutical company, which, in July 2022, expanded its dry powder inhalation (DPI) portfolio by introducing Lactohale 400. This new grade, customizable to meet specific pharmaceutical company requirements, was developed collaboratively with formulators to ensure optimal patient outcomes. Lactohale 400, a crushed, dry lactose type, caters to DPI applications requiring high flow and cohesiveness, offering different aerosolization performance than commonly used lactose carriers of the same particle size due to its anhydrous nature.

Major companies are increasingly adopting a strategic partnership approach to develop inhaled medications, particularly for treating lung infections. This collaborative strategy involves leveraging each other's strengths and resources for mutual benefits. A noteworthy partnership was announced in November 2023 between Qnovia, Inc., a US-based pharmaceutical and medtech company, and the University of Virginia (UVA), a US-based public research university. This collaboration aims to advance novel inhaled medication alternatives for the treatment of bacterial infections in the lungs by combining Qnovia's expertise in inhaled medicine delivery with UVA's exclusive array of antimicrobial peptides. The joint effort targets antibiotic-resistant and biodefense germs that can cause life-threatening illnesses, introducing two new assets-QN-05 for pneumonia and QN-06 for lung infections caused by Bacillus anthracis, the organism triggering anthrax-into Qnovia's development pipeline.

In June 2022, Kindeva Drug Delivery L.P., a U.S.-based company specializing in drug-device combination products, acquired iPharma Labs, Inc. This acquisition allows Kindeva Drug Delivery to enhance its expertise in inhalation therapies, streamline the drug development process, and accelerate market access for innovative respiratory solutions. iPharma Labs, Inc. is also a U.S.-based manufacturing company that focuses on the production of inhaled drugs and formulations.

Major companies operating in the inhalable drugs market include Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Catalent Inc., Sumitomo Pharma Co. Ltd., Intertek Group plc, AptarGroup Inc., Cipla Inc., Glenmark Pharmaceuticals Inc., Piramal Pharma Ltd., Zambon S.p.A., Sunovion Pharmaceuticals Inc., Nelson Laboratories LLC, Vectura Group Limited, Abiogen Pharma, Quotient Sciences, AeroGen Pharma, Alaxia S.A.S., Pharmaxis Ltd., Avalyn Pharma Inc., TFF Pharmaceuticals Inc.

North America was the largest region in the inhalable drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the inhalable drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The inhalable drugs market consists of sales of orally inhaled drug products, corticosteroids, and ribavirin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalable Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhalable drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalable drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhalable drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Aerosol; Dry Powder Formulation; Spray
• 2) By Distribution Channel: Hospital Pharmacy; Pharmacy Stores; Other Distribution Channels
• 3) By Application: Respiratory Diseases; Non-Respiratory Diseases
• 4) By End Users: Adults; Pediatric; Geriatric
• Subsegments:
• 1) By Aerosol: Metered Dose Inhalers (MDIs); Nebulizers; Soft Mist Inhalers
• 2) By Dry Powder Formulation: Dry Powder Inhalers (DPIs); Blister Packs; Capsules
• 3) By Spray: Nasal Sprays; Oral Sprays; Subcutaneous Sprays
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Sanofi SA; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inhalable Drugs Market Characteristics

3. Inhalable Drugs Market Trends And Strategies

4. Inhalable Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Inhalable Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inhalable Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inhalable Drugs Market Growth Rate Analysis
• 5.4. Global Inhalable Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inhalable Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inhalable Drugs Total Addressable Market (TAM)

6. Inhalable Drugs Market Segmentation

• 6.1. Global Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aerosol
• Dry Powder Formulation
• Spray
• 6.2. Global Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Pharmacy Stores
• Other Distribution Channels
• 6.3. Global Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Diseases
• Non-Respiratory Diseases
• 6.4. Global Inhalable Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Pediatric
• Geriatric
• 6.5. Global Inhalable Drugs Market, Sub-Segmentation Of Aerosol, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metered Dose Inhalers (MDIs)
• Nebulizers
• Soft Mist Inhalers
• 6.6. Global Inhalable Drugs Market, Sub-Segmentation Of Dry Powder Formulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Powder Inhalers (DPIs)
• Blister Packs
• Capsules
• 6.7. Global Inhalable Drugs Market, Sub-Segmentation Of Spray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nasal Sprays
• Oral Sprays
• Subcutaneous Sprays

7. Inhalable Drugs Market Regional And Country Analysis

• 7.1. Global Inhalable Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inhalable Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inhalable Drugs Market

• 8.1. Asia-Pacific Inhalable Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inhalable Drugs Market

• 9.1. China Inhalable Drugs Market Overview
• 9.2. China Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inhalable Drugs Market

• 10.1. India Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inhalable Drugs Market

• 11.1. Japan Inhalable Drugs Market Overview
• 11.2. Japan Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inhalable Drugs Market

• 12.1. Australia Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inhalable Drugs Market

• 13.1. Indonesia Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inhalable Drugs Market

• 14.1. South Korea Inhalable Drugs Market Overview
• 14.2. South Korea Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inhalable Drugs Market

• 15.1. Western Europe Inhalable Drugs Market Overview
• 15.2. Western Europe Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inhalable Drugs Market

• 16.1. UK Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inhalable Drugs Market

• 17.1. Germany Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inhalable Drugs Market

• 18.1. France Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inhalable Drugs Market

• 19.1. Italy Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inhalable Drugs Market

• 20.1. Spain Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inhalable Drugs Market

• 21.1. Eastern Europe Inhalable Drugs Market Overview
• 21.2. Eastern Europe Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inhalable Drugs Market

• 22.1. Russia Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inhalable Drugs Market

• 23.1. North America Inhalable Drugs Market Overview
• 23.2. North America Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inhalable Drugs Market

• 24.1. USA Inhalable Drugs Market Overview
• 24.2. USA Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inhalable Drugs Market

• 25.1. Canada Inhalable Drugs Market Overview
• 25.2. Canada Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inhalable Drugs Market

• 26.1. South America Inhalable Drugs Market Overview
• 26.2. South America Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inhalable Drugs Market

• 27.1. Brazil Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inhalable Drugs Market

• 28.1. Middle East Inhalable Drugs Market Overview
• 28.2. Middle East Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inhalable Drugs Market

• 29.1. Africa Inhalable Drugs Market Overview
• 29.2. Africa Inhalable Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inhalable Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inhalable Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inhalable Drugs Market Competitive Landscape And Company Profiles

• 30.1. Inhalable Drugs Market Competitive Landscape
• 30.2. Inhalable Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Inhalable Drugs Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Plc
• 31.2. Eli Lilly and Company
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Catalent Inc.
• 31.6. Sumitomo Pharma Co. Ltd.
• 31.7. Intertek Group plc
• 31.8. AptarGroup Inc.
• 31.9. Cipla Inc.
• 31.10. Glenmark Pharmaceuticals Inc.
• 31.11. Piramal Pharma Ltd.
• 31.12. Zambon S.p.A.
• 31.13. Sunovion Pharmaceuticals Inc.
• 31.14. Nelson Laboratories LLC
• 31.15. Vectura Group Limited

32. Global Inhalable Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inhalable Drugs Market

34. Recent Developments In The Inhalable Drugs Market

35. Inhalable Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Inhalable Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inhalable Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inhalable Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer